People

People & Governance — A Failed Say-on-Pay, a Mistimed CEO Sale, a Board Trying to Catch Up

Molina has the kind of governance architecture that scores well on a checklist — independent chairman, nine independent directors out of ten, an outside chair-led stockholder roadshow, a real clawback policy, a hard ban on pledging and hedging [1] [2] [3]. It also just lost a say-on-pay vote for the first time in years [4], watched its 69-year-old CEO sell $28 million of stock at the absolute peak six weeks before the company slashed FY25 EPS guidance from $24.50 to $19 [5] [6], and saw its three-year PSU plan forfeit in full because adjusted EPS came in at $54.56 versus a $59.36 threshold [7]. The disclosed pay structure is rigorous; the disclosed outcomes tell you the rigor is real. The governance question is narrower and harder: did insiders cash out information they had on rate-and-trend imbalance before the market did, and is a 69-year-old CEO with no named successor the right person to lead the rebuild?

Verdict: B−. Structure is strong; alignment broke under stress; succession is the single biggest unresolved item.

A snapshot of the trust question

Board Size

Independent Directors

CEO Total Comp ($M, 2025)

18.34

CEO : Median Pay Ratio

228

CEO total compensation for 2025 was $18.34 million, with a 1:228 pay ratio against the $80,329 median employee — or 1:107 if the 2025 PSUs (which the company itself says are unlikely to vest) are excluded [8] [9]. Insiders as a group own 1.44% of the company — there is no founder, no controller, no promoter [10]. The float belongs to index funds: Vanguard 12.64%, BlackRock 6.77%, Capital World 6.74%, FMR (Fidelity) 5.70% [11].

The Zubretsky problem — age, retention, and a $28M sale at the peak

The single most consequential governance event of the last 18 months is not any of the formal proposals. It is what the compensation committee did off-cycle in late 2024 and what the CEO did with his vested stock in April 2025.

The grant. In response to "direct stockholder inquiries regarding the age of Mr. Zubretsky and the expected duration of his remaining tenure," the board granted a one-time off-cycle award of 146,184 performance stock units to the CEO and 53,074 to CFO Mark Keim, contingent on hitting $36 of adjusted EPS in fiscal 2027 — a target the company itself now concedes will not be reached [12]. The board's own framing makes the conflict explicit: the grant existed because shareholders had asked whether a 69-year-old CEO would stay.

The sale. On April 30, 2025, Mr. Zubretsky sold 87,500 shares on the open market at roughly $320 a share — about $28.0 million in gross proceeds, the largest insider transaction in the dataset and not made under a 10b5-1 trading plan [5]. Within twelve weeks, on July 24, the company cut FY25 adjusted EPS guidance from $24.50 to "no less than $19" because of a medical-cost spike management says had been building since the second half of 2024 [6] [13]. Guidance was cut again to "approximately $14" at Q3 [14]. Full-year 2025 adjusted EPS actually came in at $11.03 [15]. The stock traded near $145 by the time the 2026 proxy mailed [10].

The disclosure record does not say what Mr. Zubretsky knew on April 30. The disclosure record does say that medical-cost trend pressure was building from the third quarter of 2024 [13]. Without a 10b5-1 plan to point to, this is the kind of transaction governance specialists flag whether or not it crossed any legal line. Chairman Wolf, director Schapiro, and director Orlando also each sold $200,000–$485,000 of stock within three weeks of the CEO's sale, all at prices above $300 [5].

The vote. At the 2025 annual meeting, the say-on-pay proposal failed to receive majority support — a clear miss after a five-year average of more than 90% support [4]. Compensation chair Dale Wolf personally led 15 follow-up meetings reaching holders of about 64% of outstanding shares, and Wolf, CLO Jeff Barlow, and IR head Jeff Geyer were the lead engagers [16]. Their conclusion, written into this year's proxy, is striking: because the special PSUs will likely yield zero, "the negative 2025 say-on-pay vote outcome related entirely to a compensation event that is very likely non-existent in nature" [17]. Translation: the pay event shareholders rejected won't actually pay anything, so move on. That framing reads as defensive — it sidesteps the governance objection (off-cycle, retention-driven, under-disclosed) by retreating to the dollar outcome.

Top alignment concern. A 69-year-old CEO sold $28M of stock at a 5-year high six weeks before a 22% guidance cut, with no 10b5-1 plan and no named internal successor. The board has done the procedural things — outreach, a written letter, a clawback policy on the books since October 2023 — but has not addressed the structural question of CEO succession in any disclosure we can find.

The people running this company

A lean executive team, deep insurance and managed-care experience, but skewed late-career. Mr. Zubretsky is 69 and has been CEO since November 2017 [18]. CFO Mark Keim (60) has been in the seat since February 2021 after joining Molina in 2018 from The Hanover Insurance Group; before that, Aetna and GE Capital [19]. COO James Woys (67) was elevated in May 2023 after a 30-year career at Health Net, where he was CFO, COO, and president of government services [19]. Only Mr. Zubretsky and CLO Jeff Barlow are parties to employment agreements with the company [19].

No Results

The five named executive officers are listed here in their 2025 Summary Compensation Table form [8]. Note Keim's 17.6% base-salary bump (from $850k to $1.0M) — the only base-pay increase among NEOs in 2025 [20]. The succession story is the conspicuous absence: no chief operating officer in line for the top job that the proxy talks about, no internal hand-up named beyond what the corporate-governance and nominating committee describes as "succession planning for the president and chief executive officer" reviewed by the full board [21].

Pay: structurally tough, outcomes prove it

For a buy-side reader, the most reassuring chart in the entire governance file is this one: 2025 cash bonuses were zero for every named executive officer because adjusted EPS of $11.03 came in below the threshold required for any short-term incentive payout [15]. And the entire 2023-vintage PSU grant — 33,967 PSUs at target for Mr. Zubretsky — was forfeited without payment because three-year adjusted EPS of $54.56 came in below the $59.36 threshold [7].

In 2025 the SEC "compensation actually paid" calculation for Mr. Zubretsky comes to negative $15.3 million — i.e. the mark-to-market collapse of his unvested equity exceeded his cash compensation by that amount, with $21.9 million of fair-value erosion booked on unvested awards [22] [23]. That is what an at-risk pay program is supposed to do when the company misses, and it did. The compensation mix supports the result: 91% of CEO pay is in long-term incentives, 9% in base salary [24], and 60% of the LTI mix is PSUs tied to cumulative adjusted EPS over three years [25].

The peer group used for the 2025 study is the same as 2024: a 16-company set that includes the right managed-care names (Centene, Elevance, Humana, Cigna) alongside life-insurance peers (Aflac, MetLife, Prudential), MedTech (BDX, BSX), labs (LH, DGX), hospitals (HCA, THC, UHS, CYH, DVA) [26]. It is a defensible group on size; it is loose on business model, which is a chronic critique of managed-care benchmarking.

Insider behavior — read the buys, not just the sells

The CEO's $28M sale gets the headline, but the picture is more nuanced when you trace every Form 4 in the file. The sells clustered at the price peak. The post-collapse signal is two small but unambiguous open-market buys.

No Results

The COO bought 10,000 shares at $156 on August 4, 2025 in two open-market lots totaling roughly $1.56 million — his largest disclosed open-market purchase [27]. Director Richard Zoretic added 800 shares at $125.16 on February 11, 2026 for $100,128 [27]. For Mr. Zoretic and Mr. Woys, that is real cash going in near the bottom — credible alignment with the recovery thesis. Chairman Wolf, director Romney, and director Schapiro have been periodic small sellers throughout 2024–2026; on a cumulative basis these are not large positions to begin with [27].

The pledging story is clean: the company's insider-trading policy prohibits directors and executive officers from pledging Molina shares, full stop [2]. So is the hedging picture: directors, NEOs, VPs and subsidiary officers are barred from hedging, short-selling, short-swing trading, buying or selling Molina options, or using margin accounts to hold Molina stock [3]. Each NEO satisfied the stock-ownership guideline (5x base salary for the CEO; 3x for other NEOs) as of December 31, 2025 [28]. Mr. Zubretsky beneficially owns 373,465 shares — roughly $54 million at the March-2026 proxy price [10]. Not a control stake, but not nominal either.

Board: independent on paper, gray on age, and three directors past the new term limit

Ten directors, nine independent under NYSE rules and Molina's Corporate Governance Guidelines [29]. The chairman (Dale Wolf, ex-CEO of Coventry Health Care) and the CEO are separated — Wolf has been independent chair since May 2017, and Ronna Romney has been vice-chair since the same month [1]. Healthcare expertise is the clear strength — five of ten directors come straight out of payer or provider operating roles (Wolf at Coventry, Zoretic at WellPoint/Amerigroup, Lockhart at Sutter Health, Soistman at eHealth/Aetna, Brasier as a corporate-finance generalist with audit-committee expertise) [29].

No Results

Where the board looks less independent is age and tenure. Median age is approximately 69; four directors are over 70 (Orlando 74, Romney 82, Schapiro 70, Wolf 71) [29]. Ronna Romney has been on the board since the 2003 IPO — 23 years; Steven Orlando since 2005 — 21 years; Wolf since 2013 — 13 years [29]. The board adopted a 12-year term limit for new independent directors in 2020, but that limit grandfathers the three longest-serving members [30]. Two new directors (Grohowski in 2025, Soistman as a 2026 nominee) reset the average a little [29], but a board where the CEO is 69 and the average independent director is 70 is not equipped to challenge a 69-year-old CEO on his own succession.

Note Mr. Soistman, the 2026 nominee, is himself 69 — the new director adds expertise (ex-CEO of eHealth, former Aetna president of government services, decades at Coventry and BlueCross BlueShield Maryland) but does not change the age profile [29].

Committee structure. Five standing committees: Audit (Orlando, chair), Compensation (Wolf, chair), Corporate Governance & Nominating (Romney, chair), Compliance & Quality (Zoretic, chair), and Finance (Schapiro, chair) [29]. Concentration of chair roles in the longest-serving directors is the structural read.

Related-party. During 2025 the only disclosed related-person transaction was the continued employment of George Romney, son of Vice-Chair Ronna Romney, at a base salary of approximately $157,590 — above the $120,000 disclosure threshold but trivial against a $20M company-wide pay run [31].

Auditor. Ernst & Young LLP is the independent auditor; total fees in 2025 were $6,785k ($5,945k audit + $790k audit-related + $50k tax), versus $6,790k in 2024 [32]. Audit fees are 88% of total — a clean ratio, with no tax-strategy or consulting spend that would create an auditor-independence concern [32].

Shareholder rights. This year's most material governance proposal is Proposal 5 — an amendment that would allow stockholders holding at least 20% of voting power to call a special meeting [33]. The backstory matters: at the 2025 AGM, stockholders passed a non-binding proposal asking the board to set the threshold at 10%; the board is now bringing back 20% as the floor [33]. That gap — between what stockholders voted for and what the board is now asking them to ratify — is small in dollar terms but is the second-most informative governance datapoint after the failed say-on-pay. It tells you the board's instinct under pressure is to negotiate down, not adopt.

What we couldn't pin down (and where the open questions sit)

Whether Mr. Zubretsky's April 30, 2025 sale was preceded by access to internal data not yet disclosed publicly. The proxy and 10-K do not say.
Whether the board has done formal CEO succession work beyond the high-level reference on proxy p.28. None is disclosed.
The age of CLO Jeff Barlow and EVP-Medicaid Debra Bacon, and how many years they have at Molina — the proxy does not list ages for non-CEO NEOs in the bios we read, and the document was the proxy itself, not a search of the 10-K signature page.

Verdict

Governance grade: B−. Structure is at the strong end of what disclosure rules require — independent chair, 9/10 independent board, clawback, hedging/pledging bans, real pay-for-performance proven by zero cash bonuses and a fully forfeited 2023 PSU vintage. But on the things that matter most under stress — CEO succession, the optics of a $28M peak-price insider sale outside a 10b5-1 plan, and the response to a failed say-on-pay vote — the board is one step behind. The single thing most likely to move this grade up is a credible, named internal CEO successor and the disclosure that comes with it.

References

Generated Jun 19, 2026 10:03 UTC